share_log

Viatris Announces Publication Of Phase 2b CARE Study Results For Cenerimod, Demonstrating Efficacy In Moderate-To-Severe Lupus

Viatris Announces Publication Of Phase 2b CARE Study Results For Cenerimod, Demonstrating Efficacy In Moderate-To-Severe Lupus

Viatris 宣佈發佈了 20億 CARE 研究結果,顯示 Cenerimod 在中度至重度狼瘡中的有效性。
Benzinga ·  12/18 20:03

Biomarker data from CARE study characterizing cenerimod's mechanism of action in systemic lupus erythematosus also published in the Annals of the Rheumatic Diseases

CARE研究的生物標誌物數據描述了cenerimod在系統性紅斑狼瘡中的作用機制,該數據也發表在《風溼病年鑑》上。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論